From: Optimization of personalized therapies for anticancer treatment
 | % of samples treated | K | f | Markers | Target | ||
---|---|---|---|---|---|---|---|
c | 1 | 2 | 3 | 3 | 3 | 3 | 3 |
Embelin | 0.7 | 5.9 | 31.5 | 2 | 13 | lung: small_cell_carcinoma,TP53:wt | XIAP |
Nutlin-3a | 4.1 | 8.0 | 24.5 | 2 | 11 | TP53:wt,RB1:wt | MDM2 |
Bicalutamide | 1.3 | 3.9 | 21.4 | 2 | 11 | ALK:wt,KRAS:0 | Androgen receptor (ANDR) |
XMD8-85 | 1.0 | 5.7 | 19.5 | 2 | 9 | CDKN2A:wt,malignant_melanoma | ERK5 (MK07) |
Shikonin | 1.7 | 1.7 | 11.8 | 1 | 2 | TP53:wt | unknown |
NVP-BEZ235 | 0.6 | - | 8.0 | 2 | 4 | PTEN:wt,EZH2:wt | PI3K (Class 1) and mTORC1/2 |
CI-1040 | 1.8 | 3.8 | 7.6 | 2 | 6 | malignant_melanoma,TP53:p.R273H | MEK1/2 |
EHT 1864 | 1.1 | 3.5 | 7.1 | 1 | 2 | lung: small_cell_carcinoma | Rac GTPases |
BMS-754807 | - | 4.1 | 7.0 | 2 | 14 | neuroblastoma,KRAS:p.G12V | IGF1R |
PLX4720 | 0.8 | 3.5 | 6.9 | 2 | 13 | BRAF:p.V600E,MSH2:wt | BRAF |
BX-795 | 0.7 | 5.7 | 6.3 | 2 | 14 | glioma,KRAS:+ | TBK1, PDK1, IKK, AURKB/C |
AKT inhibitor VIII | 2.4 | 5.6 | 6.3 | 2 | 9 | lung: NSCLC: adenocarcinoma,EGFR:wt | AKT1/2 |
AZD6482 | 3.8 | 6.2 | 6.3 | 1 | 2 | glioma | PI3Kb (P3C2B) |
RDEA119 | 3.9 | 7.4 | 6.0 | 2 | 13 | malignant_melanoma,BRCA1:0 | MEK1/2 |
MS-275 | 4.9 | 5.9 | 5.9 | 2 | 6 | lung: small_cell_carcinoma,RB1:wt | HDAC |
BI-D1870 | 0.7 | 1.7 | 5.3 | 2 | 14 | CCND1:0,MYCN:0 | RSK1/2/3/5, PLK1, AURKB |
MG-132 | 1.4 | - | 5.2 | 1 | 2 | glioma | Proteasome |
FH535 | 1.5 | 3.6 | 5.0 | 2 | 14 | breast,CCND1:+ | unknown |
Docetaxel | 2.8 | 1.3 | 4.6 | 2 | 9 | upper_aerodigestive_tract,EGFR:wt | Microtubules |
CGP-60474 | - | 2.8 | 4.3 | 1 | 2 | CDKN2a(p14):p.? | CDK1/2/5/7/9 |
AS601245 | 1.7 | 2.5 | 4.2 | 2 | 7 | ovary,osteosarcoma | JNK |
NVP-TAE684 | 1.5 | 3.8 | 4.2 | 1 | 1 | APC:wt,stomach | ALK |
Epothilone B | 1.3 | 1.4 | 4.1 | 2 | 7 | PIK3CA:p.E545K,TP53:p.R248W | Microtubules |
Camptothecin | 2.9 | 3.8 | 4.1 | 2 | 7 | AML,lymphoblastic T cell leukaemia | TOP1 |
Vorinostat | 4.1 | 5.7 | 4.1 | 1 | 2 | MYCN:+ | HDAC inhibitor Class I, IIa, IIb, IV |
A-443654 | 1.4 | 3.6 | 4.1 | 1 | 1 | SMAD4:wt | AKT1/2/3 |
PD-0325901 | 1.1 | 2.1 | 3.9 | 2 | 11 | large_intestine,VHL:0 | MEK1/2 |
RO-3306 | 1.5 | 3.2 | 3.9 | 2 | 11 | cervix,MYCL1:0 | CDK1 |
17-AAG | 2.2 | 2.2 | 3.8 | 2 | 6 | STK11:wt,MET:0 | HSP90 |
S-Trityl-L-cysteine | 1.1 | 3.5 | 3.8 | 1 | 1 | FBXW7:wt | KIF11 |
ZM-447439 | 0.1 | 1.3 | 3.6 | 2 | 7 | lung: NSCLC: large cell,RB1:- | AURKB |
Vinblastine | 1.4 | 2.2 | 3.2 | 2 | 13 | upper_aerodigestive_tract,IDH1:0 | Microtubules |
Paclitaxel | 0.1 | 2.5 | 3.2 | 2 | 11 | oesophagus,TSC1:wt | Microtubules |
AICAR | 0.6 | 1.7 | 2.9 | 1 | 1 | KDM6A:wt | AMPK agonist |
BIBW2992 | 1.4 | 2.2 | 2.9 | 1 | 1 | ERBB2:0 | EGFR, ERBB2 |
JNK-9L | - | - | 2.7 | 1 | 2 | AML | JNK |
BAY 61-3606 | 1.0 | 2.1 | 2.7 | 1 | 2 | Ewings sarcoma | SYK |
AMG-706 | - | - | 2.7 | 1 | 2 | Ewings sarcoma | VEGFR, RET, c-KIT, PDGFR |
AZ628 | - | 2.2 | 2.5 | 2 | 9 | KRAS:p.G12D,FGFR3:0 | BRAF |
BMS-536924 | - | 1.1 | 2.5 | 2 | 7 | KRAS:+,MDM2:+ | IGF1R |
JW-7-52-1 | 1.1 | 1.7 | 2.5 | 1 | 2 | stomach | MTOR |
Elesclomol | 1.0 | 3.5 | 2.4 | 2 | 8 | bladder,TSC1:wt | HSP70 |
Pyrimethamine | 0.8 | 3.5 | 2.4 | 1 | 2 | pancreas | Dihydrofolate reductase (DHFR) |
KIN001-135 | 0.3 | 0.7 | 2.2 | 1 | 1 | MET:+ | IKKE |
Dasatinib | - | - | 2.0 | 2 | 13 | Renal cell carcinoma,NRAS:0 | ABL, SRC, KIT, PDGFR |
ABT-888 | 1.5 | 2.5 | 1.7 | 2 | 11 | lymphoid_neoplasm other,CDK4:0 | PARP1/2 |
BI-2536 | 2.9 | 3.1 | 1.7 | 2 | 2 | CDKN2A:p.0?,MYC:0 | PLK1/2/3 |
IPA-3 | - | - | 1.7 | 1 | 2 | B cell lymphoma | PAK |
WO2009093972 | 1.5 | 2.0 | 1.7 | 1 | 2 | soft tissue other | PI3Kb |
Methotrexate | 1.7 | 4.2 | 1.5 | 2 | 8 | lymphoblastic leukemia,GNAS:wt | Dihydrofolate reductase (DHFR) |
Roscovitine | 0.1 | 3.1 | 1.5 | 1 | 2 | Burkitt lymphoma | CDKs |
FTI-277 | 1.4 | 1.4 | 1.5 | 1 | 2 | thyroid | Farnesyl transferase (FNTA) |
PAC-1 | 1.5 | 1.5 | 1.5 | 1 | 2 | Burkitt lymphoma | CASP3 activator |
CCT018159 | 1.3 | 3.5 | 1.4 | 2 | 14 | osteosarcoma,PTEN:0 | HSP90 |
PF-4708671 | 0.7 | 0.8 | 1.4 | 2 | 13 | Myeloma,BRCA1:wt | p70 S6KA |
TW 37 | 0.8 | 1.1 | 1.4 | 2 | 6 | MLH1:wt,APC:0 | BCL-2, BCL-XL |
MK-2206 | 1.3 | 1.4 | 1.4 | 1 | 2 | endometrium | AKT1/2 |
JNK Inhibitor VIII | - | - | 0.3 | 1 | 2 | AML | JNK |
Obatoclax Mesylate | - | - | 0.1 | 2 | 2 | RB1:-,CDK6:+ | BCL-2, BCL-XL, MCL-1 |